Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.47 |
| ▸ | MME | P08473 | 7/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350402 | 0.91 | MME (0.48) | ACEMMECPA1ACE2 | |
| SCHEMBL30918334 | 0.81 | NPY4R (0.47) | — | |
| SCHEMBL30958910 | 0.79 | ACE (0.58) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL27653020 | 0.76 | SLC7A5 (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31025673 | 0.76 | SLC7A5 (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL1574161 | 0.76 | SLC7A5 (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30439955 | 0.76 | SLC7A5 (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL1574158 | 0.76 | SLC7A5 (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL4073351 | 0.74 | ACE (0.65) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL8903262 | 0.74 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| WO-2025243217-A1 | CRYSTAL FORMS OF PEPTIDE MOLECULES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | ACE 1672/4885MME 406/4885CPA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.